Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 409 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR COVID-19 in people with cancer – what we know so far December 4, 2020 FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy March 16, 2023 Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... November 18, 2020 Co-Existing with COVID-19: Should I go back to work? Do I... June 19, 2020 Load more HOT NEWS Do Black Lives Matter Less Than Those of Cancer Survivors? Better together: improving brain tumour treatment Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age... Dr Ian Walker on Smoking: ‘An unequal burden, but a fixable...
